title: Low-molecular-weight heparin or dual antiplatelet therapy is more effective than aspirin alone in preventing early neurological deterioration and improving the 6-month outcome in ischemic stroke patients.
abstract: OBJECTIVE
  Dual antiplatelet therapy (DAT) with clopidogrel and aspirin has been shown to confer greater protection against early neurological deterioration (END) and early recurrent ischemic stroke (ERIS) than aspirin alone in patients who have experienced an acute ischemic stroke. However, few studies have compared the effects of anticoagulation therapy with low-molecular-weight heparin (LMWH), DAT, and aspirin.
  
  
  METHODS
  Patients with acute ischemic stroke (n=1,467) were randomized to therapy groups receiving aspirin (200 mg daily for 14 days, followed by 100 mg daily for 6 months), DAT (200 mg of aspirin and 75 mg of clopidogrel daily for 14 days, then 100 mg of aspirin daily for 6 months), or LMWH (4,000 antifactor Xa IU of enoxaparin in 0.4 mL subcutaneously twice daily for 14 days, followed by 100 mg of aspirin daily for 6 months). The effects of these treatment strategies on the incidence of END, ERIS, and deep-vein thrombosis (DVT) were observed for 10-14 days after treatment, and their impacts on a good outcome were evaluated at 6 months.
  
  
  RESULTS
  The DAT and LMWH were associated with a more significant reduction of END and ERIS within 14 days compared with aspirin-alone therapy. In addition, LMWH was associated with a significantly lower incidence of DVT within 14 days. At 6 months, DAT or LMWH improved the outcome among patients aged >70 years and those with symptomatic stenosis in the posterior circulation or basilar artery compared with aspirin.
  
  
  CONCLUSIONS
  LMWH or DAT may be more effective than aspirin alone for reducing the incidence of END and ERIS within 14 days, and is associated with improved outcomes in elderly patients and those with stenosis in the posterior circulation or basilar artery at 6 months poststroke.
authors: Department of Neurology, People's Hospital of Deyang City, Deyang, China.
authors: Xingyang
authors: X
authors: Yi
authors: Department of Neurology, Third Affiliated Hospital of Wenzhou Medical College, Wenzhou, China.
authors: Wanzhang
authors: W
authors: Chi
authors: Department of Neurology, People's Hospital of Deyang City, Deyang, China.
authors: Chun
authors: C
authors: Wang
authors: Department of Neurology, People's Hospital of Deyang City, Deyang, China.
authors: Biao
authors: B
authors: Zhang
authors: Department of Neurology, Third Affiliated Hospital of Wenzhou Medical College, Wenzhou, China.
authors: Jing
authors: J
authors: Lin
keywords: acute ischemic stroke; dual antiplatelet therapy; early neurological deterioration; low-molecular-weight heparin; outcomes
references: J Stroke Cerebrovasc Dis. 2014 Aug;23(7):1975-81
references: 24739593
references: Int J Stroke. 2013 Oct;8(7):535-9
references: 23231453
references: Lancet. 1996 Nov 16;348(9038):1329-39
references: 8918275
references: Stroke. 1995 Jan;26(1):14-20
references: 7839388
references: Lancet Neurol. 2007 May;6(5):407-13
references: 17434095
references: Stroke. 2010 Aug;41(8):1636-40
references: 20616323
references: Thromb Haemost. 1998 Sep;80(3):512-8
references: 9759636
references: J Thromb Thrombolysis. 2012 Aug;34(2):269-75
references: 22466814
references: N Engl J Med. 2013 Jul 4;369(1):11-9
references: 23803136
references: Lancet. 2001 Sep 1;358(9283):702-10
references: 11551576
references: Stroke. 1996 Jun;27(6):1084-7
references: 8650718
references: N Engl J Med. 2012 Aug 30;367(9):817-25
references: 22931315
references: Neurology. 1993 Aug;43(8):1528-33
references: 8351006
references: N Engl J Med. 2001 Aug 16;345(7):494-502
references: 11519503
references: JAMA. 1998 Apr 22-29;279(16):1265-72
references: 9565006
references: Neurology. 2000 Aug 22;55(4):490-7
references: 10953179
references: Cerebrovasc Dis. 2008;25(4):355-61
references: 18305387
references: N Engl J Med. 2008 Sep 18;359(12):1238-51
references: 18753638
references: Lancet. 2004 Jul 24-30;364(9431):331-7
references: 15276392
references: JAMA. 2002 Nov 20;288(19):2411-20
references: 12435254
references: Eur Neurol. 2007;57(2):96-102
references: 17179712
references: Arch Neurol. 2012 Nov;69(11):1454-60
references: 22893265
references: Stroke. 2010 Sep;41(9):1990-5
references: 20705933
references: Stroke. 2012 Feb;43(2):346-9
references: 22076004
references: Cerebrovasc Dis. 2012;33(3):248-54
references: 22261731
references: Stroke. 2012 Dec;43(12):3313-8
references: 23160885
references: J Clin Neurol. 2006 Mar;2(1):29-33
references: 20396482
references: Stroke. 2000 Nov;31(11):2641-7
references: 11062288
references: Circulation. 2003 Jun 17;107(23):2908-13
references: 12796140
references: J Stroke Cerebrovasc Dis. 2014 Jul;23(6):1537-44
references: 24656240
references: Am Heart J. 2010 Sep;160(3):380-386.e1
references: 20826243
references: Lancet. 1997 May 31;349(9065):1569-81
references: 9174558
references: N Engl J Med. 1995 Dec 14;333(24):1588-93
references: 7477193
references: N Engl J Med. 2006 Apr 20;354(16):1706-17
references: 16531616
references: Neurology. 1999 Jul 13;53(1):122-5
references: 10408547
references: Eur Heart J. 1998 Oct;19(10):1538-46
references: 9820993
references: Stroke. 2009 Jun;40(6):e443-50
references: 19390076
references: Neurosurgery. 2003 May;52(5):1033-9; discussion 1039-40
references: 12699544
references: Lancet Neurol. 2010 May;9(5):489-97
references: 20335070
references: Circulation. 2005 May 3;111(17 ):2233-40
references: 15851601
references: Lancet. 1997 Jun 7;349(9066):1641-9
references: 9186381
references: Cerebrovasc Dis. 2013;36(2):131-8
references: 24029712
references: Neurology. 2006 Oct 10;67(7):1275-8
references: 17030766
references: Lancet Neurol. 2007 Nov;6(11):961-9
references: 17931979